Improved ex vivo blood compatibility of central venous catheter with noble metal alloy coating

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 104, Issue 7, 2016, Pages 1359-1365

  Vafa Homann, Manijeh ^a   Johansson, Dorota ^b   Wallen, Håkan ^c   Sanchez, Javier ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Biovitrum AB   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

blood compatibility; central line associated blood stream infection; central Venous catheter; nobel metal alloy coating; surface modification

Indexed keywords

ADHESION; BIOMATERIALS; BIOMEDICAL ENGINEERING; CATHETERS; CELL ADHESION; COATINGS; METAL CLADDING; PLATELETS; PRECIOUS METALS; SURFACE TREATMENT;

BIOMEDICAL MATERIAL; BLOOD COMPATIBILITY; BLOOD STREAMS; CHANDLER-LOOP MODEL; COMPLEMENT ACTIVATIONS; METAL ALLOYS; MICROBIOLOGICAL ANALYSIS; NOBLE METAL ALLOYS;

BLOOD;

ALLOY; CHLORHEXIDINE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5B; FIBRIN; HEMOGLOBIN; SULFADIAZINE SILVER; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BACTIGUARD INFECTION PROTECTION CENTRAL VENOUS CATHETER; BIOFILM; BLOOD COMPATIBILITY; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EX VIVO STUDY; FIBRIN DEPOSITION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYSIS ASSAY; HUMAN; INFECTION PREVENTION; MATERIAL COATING; MICROBIAL ADHESION; NORMAL HUMAN; SURFACE PROPERTY; THROMBOCYTE COUNT;

EID: 84991266668     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.33403     Document Type: Article

References (29)

1. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122:160–166.
2. ScottRD, II. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. Atlanta, GA: Centers for Disease Control and Prevention; 2009.
3. European Centre for Disease Prevention and Control. Surveillance of Healthcare-Associated Infections in Europe. Stockholm: ECDC; 2007.
4. Di Filippo A, Casini A, de Gaudio AR. Infection prevention in the intensive care unit: Review of the recent literature on the management of invasive devices. Scand J Infect Dis 2011;43:243–250.
5. Francolini I, Donelli G. Prevention and control of biofilm-based medical-device-related infections. FEMS Immunol Med Microbiol 2010;59:227–238.
6. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. Health care-associated infections: A meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039–2046.
7. Chugh TD, Khan ZU. Intravascular device-related infections: Antimicrobial catheters as a strategy for prevention. J Hosp Infect 2001;49:1–3.
8. World Health Organization. Preventing Bloodstream Infections From Central Line Venous Catheters. Geneva: WHO; 2011.
9. Leistner R, Hirsemann E, Bloch A, Gastmeier P, Geffers C. Costs and prolonged length of stay of central venous catheter-associated bloodstream infections (CVC BSI): A matched prospective cohort study. Infection 2014;42:31–36.
10. Beattie M, Taylor J. Silver alloy vs. uncoated urinary catheters: A systematic review of the literature. J Clin Nurs 2011;20:2098–2108.
11. Goldschmidt H, Hahn U, Salwender HJ, Haas R, Jansen B, Wolbring P, Rinck M, Hunstein W. Prevention of catheter-related infections by silver coated central venous catheters in oncological patients. Zentralbl Bakteriol 1995;283:215–223.
12. Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt H, Ho AD. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: A prospective comparison of silver-coated and uncoated catheters. Cancer 2002;94:245–251.
13. Gabriel MM, Sawant AD, Simmons RB, Ahearn DG. Effects of silver on adherence of bacteria to urinary catheters: In vitro studies. Curr Microbiol 1995;30:17–22.
14. Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A 2003;67:458–466.
15. Fink H, Hong J, Drotz K, Risberg B, Sanchez J, Sellborn A. An in vitro study of blood compatibility of vascular grafts made of bacterial cellulose in comparison with conventionally-used graft materials. J Biomed Mater Res A 2011;97:52–58.
16. Sinn S, Scheuermann T, Deichelbohrer S, Ziemer G, Wendel HP. A novel in vitro model for preclinical testing of the hemocompatibility of intravascular stents according to ISO 10993-4. J Mater Sci Mater Med 2011;22:1521–1528.
17. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 2004;138:439–446.
18. Lappegard KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, Mollnes TE. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 2008;87:129–135.
19. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007;44:82–94.
20. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25:5681–5703.
21. Sefton MV, Gemmell CH, Gorbet MB. What really is blood compatibility? J Biomater Sci Polym Ed 2000;11:1165–1182.
22. Engberg AE, Nilsson PH, Huang S, Fromell K, Hamad OA, Mollnes TE, Rosengren-Holmberg JP, Sandholm K, Teramura Y, Nicholls IA, et al. Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma. Biomaterials 2015;36:55–65.
23. Rinder C, Fitch J. Amplification of the inflammatory response: Adhesion molecules associated with platelet/white cell responses. J Cardiovasc Pharmacol 1996;27(Suppl 1):S6–S12.
24. Zhang W, Lachmann PJ. Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways. J Immunol 1996;156:2599–2606.
25. Gorbet MB, Sefton MV. Complement inhibition reduces material-induced leukocyte activation with PEG modified polystyrene beads (Tentagel) but not polystyrene beads. J Biomed Mater Res A 2005;74:511–522.
26. Mollnes TE. Complement and biocompatibility. Vox Sang 1998;74(Suppl 2):303–307.
27. Hulander M, Hong J, Andersson M, Gerven F, Ohrlander M, Tengvall P, Elwing H. Blood interactions with noble metals: Coagulation and immune complement activation. ACS Appl Mater Interfaces 2009;1:1053–1062.
28. Hulander M, Lundgren A, Berglin M, Ohrlander M, Lausmaa J, Elwing H. Immune complement activation is attenuated by surface nanotopography. Int J Nanomed 2011;6:2653–2666.
29. Singhai M, Malik A, Shahid M, Malik MA, Goyal R. A study on device-related infections with special reference to biofilm production and antibiotic resistance. J Glob Infect Dis 2012;4:193–198.